Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

(2018) S Rule et al.   LEUKEMIA

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis

(2018) Areti Angeliki Veroniki et al.   Research Synthesis Methods

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management

(2017) Bronwyn C. Thorp et al.   LEUKEMIA & LYMPHOMA

A era dos novos anticoagulantes orais em Portugal

(2017) Daniel Caldeira et al.   Revista Portuguesa de Cardiologia

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

Basics of meta-analysis:I2is not an absolute measure of heterogeneity

(2017) Michael Borenstein et al.   Research Synthesis Methods

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

(2016) Darryl P. Leong et al.   BLOOD

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPACE

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

(2016) Asher Chanan-Khan et al.   LANCET ONCOLOGY

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

(2016) Tait D. Shanafelt et al.   LEUKEMIA & LYMPHOMA

Plea for routinely presenting prediction intervals in meta-analysis

(2016) Joanna IntHout et al.   BMJ Open

Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis

(2015) Daniel Caldeira et al.   American Journal of Cardiovascular Drugs

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score

(2015) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?

(2015) Tze-Fan Chao et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study

(2015) Renate B Schnabel et al.   LANCET

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis

(2015) Daniel Caldeira et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Dyspnea and Reversibility Profile of P2Y12 Antagonists: Systematic Review of New Antiplatelet Drugs

(2014) Daniel Caldeira et al.   American Journal of Cardiovascular Drugs

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

(2014) J. R. McMullen et al.   BLOOD

The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method

(2014) Joanna IntHout et al.   BMC Medical Research Methodology

Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis

(2014) Daniel Caldeira et al.   HEART

Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis

(2014) Daniel Caldeira et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis

(2014) D. Caldeira et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials

(2012) Daniel Caldeira et al.   Archives of Cardiovascular Diseases

Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials

(2011) Daniel Caldeira et al.   European Journal of Internal Medicine

GRADE guidelines: 3. Rating the quality of evidence

(2011) Howard Balshem et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

(2010) Martin J O'Donnell et al.   LANCET